Mycobacterium chelonae-like organisms are nonpigmented rapidly growing mycobacteria whose clinical significance is unknown. We evaluated 87 sporadic isolates encountered in a clinical laboratory. Most isolates (62%) were respiratory; only 2 of 54 (4%) (both from patients with AIDS) were clinically significant. Among 33 nonrespiratory isolates, 20 of 33 (or 61%) were clinically significant. Clinical diseases included posttraumatic wound infections and catheter-related sepsis. Routine biochemical features included growth inhibition by 5% NaCl (100o), a smooth colony morphology (94%), positive 3-day arylsulfatase reaction (84%), no color or a light tan color on iron uptake (100%Yo), and variable nitrate reduction (45%). Additional characteristics that helped to separate this group from M. chelonae and Mycobacterium abscessus were susceptibility to cephalothin (90%) and ciprofloxacin (100o), utilization of mannitol (94%) and citrate (83%) as carbon sources, and unique patterns of mycolic acid esters by high-performance liquid chromatography. This group was quite drug susceptible, with 100lo of isolates inhibited by amikacin, imipenem, cefoxitin, cefmetazole, and the newer quinolones ciprofloxacin and ofloxacin.
In 1982 an outbreak of peritonitis that involved the use of hospital-based automated chronic peritoneal dialysis machines was reported. Both epidemic and sporadic cases occurred over a 2-year period, with two separate dialysis centers being involved. The causative organism, a previously unrecognized nonpigmented species of rapidly growing mycobacteria, was recovered from tap water in the dialysis center as well as the dialysis machines (1) . The organism was similar to Mycobacterium chelonae (formerly M. chelonae subsp. chelonae) in that it was arylsulfatase positive at 3 days, nonpigmented, and nitrate negative and did not grow in the presence of 5% NaCl. The organism was given the tentative name of M. chelonae-like organism (MCLO) (1, 18) . Although the isolates were uniform in their biochemical reactions (1) and antimicrobial susceptibility patterns (20) , subsequent evaluation including studies of 13-lactamase electrophoretic patterns (29) suggested that a single strain of organism may have been involved, and hence, the phenotypes of sporadic isolates may vary from this initial description.
Since the report of the peritonitis outbreak, we have encountered sporadic isolates of MCLOs among isolates of rapidly growing mycobacteria submitted for susceptibility testing. The purpose of the current study was to characterize the phenotypic features of these strains, their clinical significance, and their antimicrobial susceptibility patterns. * 
MATERIALS AND METHODS
Isolates of rapidly growing mycobacteria with features of the MCLO were identified among clinical and environmental isolates submitted to the Nocardia/Mycobacterial Research Laboratory of the University of Texas for susceptibility testing. Most isolates were then characterized biochemically and for growth features at the Mycobacterial Reference Section of the Centers for Disease Control and Prevention, Atlanta, Ga., by previously described methods (18) . Selected isolates were also submitted to the National Chubu Hospital, Obu-Aichi, Japan, for testing against 103 characters that included growth characteristics, utilization of various carbohydrates as carbon and/or nitrogen sources, and growth inhibition by a variety of drugs and chemical compounds (22) .
Isolates were tested for their antimicrobial susceptibilities by the broth microdilution method (at the Texas laboratory) in cation-supplemented Mueller-Hinton broth as described previously for rapidly growing mycobacteria (20 Eighty clinical isolates submitted to the Texas laboratory for susceptibility testing, representing all of the other groups of nonpigmented rapidly growing mycobacteria encountered in the clinical laboratory, were also tested against cephalothin.
Although some strains of M. smegmatis produce a late pigment, many do not, and hence, this species is one of the groups included for comparison (26) . None of the 80 clinical strains or the 6 strains from the American Type Culture Collection (representing six taxonomic groups) had any zone of inhibition, defining the high specificity of cephalothin susceptibility for identifying isolates of MCLOs.
Three examples of MCLOs were deposited in the American Type Culture Collection. ATCC 49649 was an isolate from a patient with peritonitis and from the first described disease outbreak in Washington State in 1977 (1). It is the earliest characterized isolate of this taxonomic group and is proposed as the type strain. It is somewhat atypical in that it is cephalothin resistant and has high (>45 mm) semiquantitative catalase activity. Two other, more typical strains (ATCC 49650 and 49651) are also included. ATCC 49650 was from a neck abscess and was chosen as an example of a nitrate-positive strain. ATCC 49651 was from a postinjection buttock abscess. Both of the last two strains were from Texas. The biochemical features of these strains are included in Table 1 , and the MICs for the strains are given in Table 3 .
All isolates submitted to the Centers for Disease Control and Prevention laboratory (64 strains) were studied by HPLC. The HPLC patterns of mycolic acid esters of the new species provided an easy means of separating them from other nonpigmented, rapidly growing mycobacterial species. Table 5 .
DISCUSSION
The eponym MCLO was given to the organisms described here because of their similarity to M. chelonae (formerly M. chelonae subsp. chelonae) (13) in that they are nitrate negative, are inhibited by 5% NaCl, and fail to turn dark brown when grown on ferric ammonium citrate (iron uptake) (1). The name is now misleading, because almost 50% of these sporadic strains reduce nitrate (like M. fortuitum, M. peregnnum, and M. smegmatis), and the strains are not totally negative on iron uptake because they often produce a light tan or rust color along the edge of the slant, whereas M. chelonae does not.
A small percentage of strains (14%) of this group had negative 3-day arylsulfatase reactions, and an even smaller percentage (6%) had a negative 14-day reaction. These strains were, by other tests, similar to other members of this group. Until more weighted taxonomic tests (DNA-DNA hybridization or 16S rRNA sequencing) are performed on these isolates to determine whether these differences relate to significant genetic differences, we have elected to keep them as part of the MCLO species. The clinical data suggest that the organisms are most commonly recovered from sputum samples but are almost never associated with lung disease. We recommend follow-up or performing drug susceptibility testing only if an isolate of this group is recovered from multiple sputum samples or is from a patient with AIDS. (In the current study, almost all respiratory isolates were from single positive samples, with other samples being negative.)
In contrast, recovery of organisms of this taxonomic group from skin or blood cultures was often associated with clinical disease. The two syndromes of disease identified were catheter-associated sepsis and posttraumatic wound infections. Single positive blood cultures were often contaminated, so careful attention to the clinical setting or the presence of multiple positive blood cultures was required to confirm pathogenicity. The types of disease seen with these organisms are typical for those caused by other rapidly growing mycobacterial species, including M. fortuitum, M. chelonae, M. abscessus, and M. smegmatis (25, 26, 28 (7a) . The latter two observations suggest that these organisms are not an infrequent cause of problems with species identification, but they do not provide the true incidence of this group among consecutive clinical isolates.
A major issue to be addressed is whether current standard laboratory techniques will identify MCLOs. One key biochemical feature of this group is their growth inhibition in 5% NaCl. Usually, the inability to grow in the presence of 5% NaCl among isolates of rapidly growing mycobacteria has been limited to isolates of M. chelonae. Unfortunately, isolates of M. abscessus are often inhibited unless low temperatures are used (28°C) and incubation is done for up to 4 weeks (11). Thus, growth inhibition by 5% NaCl is not a highly specific indicator of an MCLO. It will, however, exclude nonpigmented rapidly growing species other than M. chelonae or M. abscessus, because other species grow readily on 5% NaCl (18, 25, 26) .
When recognized, the light tan or rust color of the colonies on ferric ammonium citrate is highly suggestive of MCLO because this characteristic has not been seen with other rapidly growing groups. This pattern is not always present or recognized, however. The remaining tests currently performed to define the species (18) are inadequate for recognition of the MCLO. Thus, additional laboratory tests are needed.
Three additional techniques which will provide for identification are antimicrobial susceptibility tests, carbohydrate utilization tests, and the HPLC patterns of mycolic acid esters. Susceptibility studies have not been routinely used for species or subgroup identification with mycobacteria. They have frequently been used in laboratories that perform both susceptibility testing and mycobacterial identification.
Susceptibilities to polymyxin B (27) , amikacin (27) , ciprofloxacin (19, 24) , ofloxacin (23) , and pipemidic acid (6, 19) (13, 14) will require testing of their abilities to utilize citrate, given the problems with the use of growth inhibition by 5% NaCl, as noted above. Recent studies based on DNA-DNA hybridization (13, 14) inositol (18, 25) . For MCLOs, routine isolates are positive for mannitol and citrate and negative for inositol, a pattern not identified among any other rapidly growing species or subgroup.
The third test which provided ready separation of the new species from other rapidly growing nonpigmented mycobacterial groups was HPLC of mycolic acid esters. Proposed minimal standards for inclusion in the genus Mycobacterium and for description of new Mycobacterium species of slowly growing (but not rapidly growing) species has recently been published by L&vy-Frebault and Portaels (15) . Previous studies with MCLOs demonstrated some of its growth characteristics (1, 18) . Guerrant et al. studied the high-temperature cleavage products of mycolic acids from MCLOs by gas chromatography (9) . As with other mycobacteria, pyrolysis esters C22 to C26 were identified. Interestingly, this new group contains a unique mixture of C22 and C24 mycolic acid cleavage products, while other nonpigmented rapidly growing species contain only C24 products. (The five strains of MCLOs studied were also examined in the current study.) Most of the biochemical studies and mycolic acid profiles suggested for the slowly growing species have been added in the current study. Although the available phenotypic and biochemical data suggest that MCLOs represent a distinct species, genetic relatedness studies to other nonpigmented rapidly growing mycobacteria are needed. Sequencing of selected regions of the 16S rRNA of the three MCLO strains from the American Type Culture Collection and DNA-DNA homology with other nonpigmented rapidly growing mycobacteria are ongoing.
